Dendritic cells, interleukin 12, and CD4 + lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 87-98

  Grohmann, Ursula ^a   Fioretti, Maria Cristina ^a   Bianchi, Roberta ^a   Belladonna, Maria Laura ^a   Ayroldi, Emira ^a   Surace, Daniela ^b   Silla, Silvia ^a   Puccetti, Paolo ^a,c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Dendritic cells; Energy; IL 12; Tumor peptides

Indexed keywords

CD4 ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 12; EPITOPE; HLA ANTIGEN CLASS 2; IMMUNOLOGICAL ADJUVANT; PEPTIDE; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TUMOR REJECTION ANTIGEN P815A, MOUSE;

ANIMAL CELL; CLONAL ANERGY; CONFERENCE PAPER; DENDRITIC CELL; HELPER CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION; ANIMAL; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; SYNTHESIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLONAL ANERGY; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MICE; PEPTIDES; RECOMBINANT PROTEINS;

EID: 0030717709     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Boon, T., Cerottini, J.-C., Van den Eynde, B., Van der Bruggen, P., and Van Pel, A., Tumor antigens recognized by T lymphocytes, Annu. Rev. Immunol., 12, 337-365, 1994.
2. Steinman, R. M., Dendritic cells and immune-based therapies, Exp. Hematol., 24, 859-862, 1996.
3. Rosenberg, S. A., The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens, Annu. Rev. Med., 47, 481-491, 1996.
4. Meurer, M. J., Storkus, W. J., Kirkwood, J. M., and Lotze, M. T., New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines, Melanoma Res., 6, 11-24, 1996.
5. Romagnani, S., Development of Th1- or Th2-dominated immune responses: what about the polarizing signals? Int. J. Clin. Lab. Res., 26, 83-98, 1996.
6. Wu, T. C., Guarnieri, F. G., Staveley-O'Carroll, K. F., Viscidi, R. P., Levitsky, H. I., Hedrick, L., Cho, K. R., August, J. T., and Pardoll, D. M., Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens, Proc. Natl. Acad. Sci. U.S.A., 92, 1671-1675, 1995.
7. Mosmann, T. R. and Sad, S., The expanding universe of T-cell subsets: Th1, Th2 and more, Immunol. Today, 17, 138-146, 1996.
8. Van der Meide, P. H. and Schellekens, H., Cytokines and the immune response, Biotherapy, 8, 243-249, 1996.
9. Seder, R. A., The role of interleukin 12 in the regulation of Th1 and Th2 differentiation, Res. Immunol., 146, 473-476, 1995.
10. Young, J. W. and Inaba, K., Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity, J. Exp. Med., 183, 7-11, 1996.
11. Boon, T., Toward a genetic analysis of tumor rejection antigens, Adv. Cancer Res., 58, 177-210, 1992.
12. + T cell reactivity, Eur. J. Immunol., 24, 1446-1452, 1994.
13. Kündig, T. M., Althage, A., Hengartner, H., and Zinkernagel, R. M., Skin test to assess virus-specific cytotoxic T-cell activity, Proc. Natl. Acad. Sci. U.S.A., 89, 7757-7761, 1992.
14. Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E., and Boon, T., The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice, J. Exp. Med., 173, 1373-1384, 1991.
15. Lethé, B., Van den Eynde, B., Van Pel, A., Corradin, G., and Boon, T., Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide, Eur. J. Immunol., 22, 2283-2288, 1992.
16. d and is recognized by cytotoxic T lymphocytes against mouse tumor P815, Eur. J. Immunol., 24, 2740-2745, 1994.
17. Uyttenhove, C., Maryansky, J., and Boon, T., Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression, J. Exp. Med., 157, 1040-1052, 1983.
18. - or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur. J. Immunol., 25, 2797-2802, 1995.
19. + T cells, J. Immunol., 154, 5071-5079, 1995.
20. Ma, X., Aste-Amezaga, M., and Trinchieri, G., Regulation of interleukin-12 production, Ann. N.Y. Acad. Sci., 795, 13-25, 1996.
21. Brunda, M. J., Luistro, L., Rumennik, L., Wright, R. B., Dvorozniak, M., Aglione, A., Wigginton, J. M., Wiltrout, R. H., Hendrzak, J. A., and Palleroni, A. W., Antitumor activity of interleukin 12 in preclinical models, Cancer Chemother. Pharmacol., 38, S16-21, 1996.
22. Gately, M. K. and Mulqueen, M. J., Interleukin-12: potential clinical applications in the treatment and prevention of infectious diseases, Drugs, 52(S2), 18-25, 1996.
23. Gazzinelli, R. T., Molecular and cellular basis of interleukin 12 activity in prophylaxis and therapy against infectious diseases, Mol. Med. Today, 2, 258-267, 1996.
24. Seder, R. A., Kelsall, B. L., and Jankovic, D., Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease, J. Immunol., 157, 2745-2748, 1996.
25. Noguchi, Y., Richards, E. C., Chen, Y.-T., and Old, L. J., Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma, Proc. Natl. Acad. Sci. U.S.A., 92, 2219-2223, 1995.
26. Hegde, S. P., Bright, J. J., Kausalya, S., and Kahr, A., AK-5 tumor induced expression of interleukin-12: role of IL-12 in NK-mediated AK-5 regression, Cell. Immunol., 162, 241-247, 1995.
27. + T cells into IL-4-secreting cells, J. Immunol., 152, 5180-5188, 1994.
28. Pfeiffer, C., Stein, J., Southwood, S., Katelaar, H., Sette, A., and Bottomly, K., Altered peptide ligands can control CD4 T lymphocytes differentiation in vivo, J. Exp. Med., 181, 1569-1574, 1995.
29. Bianchi, R., Grohmann, U., Belladonna, M. L., Silla, S., Fallarino, F., Ayroldi, E., Fioretti, M. C., and Puccetti, P., IL-12 is both required and sufficient for initiating T-cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells, J. Immunol., 157, 1589-1597, 1996.
30. + T cells, Annu. Rev. Immunol., 12, 635-673, 1994.
31. Wolf, S. F., Sieburth, D., and Sypeck, J., Interleukin 12: a key modulator of immune function, Stem Cells, 12, 154-168, 1994.
32. + T cells in cancer immunotherapy, Curr. Opin. Immunol., 6, 741-745, 1994.
33. Grohmann, U., Bianchi, R., Ayroldi, E., Belladonna, M. L., Surace, D., Fioretti, M. C., and Puccetti, P., A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state, J. Immunol., 158, 3593-3602, 1997.
34. Heeg, K. and Wagner, H., Induction of responsiveness in superantigen-induced anergic T cells. Role of ligand density and costimulatory signals, J. Immunol., 155, 83-92, 1995.
35. Lombardi, G., Sidhu, S., Batchelor, R., and Lechler, R., Anergic T cells as suppressor cells in vitro, Science, 264, 1587-1589, 1994.
36. Adorini, L., Gregori, S., Magram, J., and Trembleau, S., The role of IL-12 in the pathogenesis of Th1 cell-mediated autoimmune diseases, Ann. N.Y. Acad. Sci., 795, 208-215, 1996.
37. Leonard, J. P., Waldburger, K. E., and Goldman, S. J., Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin-12, J. Exp. Med., 181, 381-386, 1995.
38. Germann, T., Szeliga, J., Hess, H., Storkel, S., Podlaski, F. J., Gately, M. K., Schmitt, E., and Rüde, E., Administration of IL-12 in combination with type n collagen induces severe arthritis in DBA/1 mice, Proc. Natl. Acad. Sci. U.S.A., 92, 4823-4827, 1995.
39. Florquin, S. and Goldman, M., Immune regulatory mechanisms of T-cell dependent shock induced by a bacterial superantigen in mice, Infect. Immun., 64, 3443-3445, 1996.
40. Johnson, H. M., Torres, B. A., and Soos, J. M., Superantigens: structure and relevance to human disease, Proc. Soc. Exp. Biol. Med., 212, 99-109, 1996.
41. Miethke, T., Wahl, C., Heeg, K., and Wagner, H., Superantigens: the paradox of T-cell activation versus inactivation, Int. Arch. Allergy Immunol., 106, 3-7, 1995.
42. Quill, H., Anergy as a mechanism of peripheral T cell tolerance, J. Immunol., 156, 1325-1327, 1996.
43. fyn expression, Eur. J. Immunol., 24, 558-565, 1994.
44. Nelson, C. A., Petzold, S. J., and Unanue, E. R., Identification of two distinct properties of class II major histocompatibility complex-associated peptides, Proc. Natl. Acad. Sci. U.S.A., 90, 1227-1231, 1993.
45. Boon, T. and van der Bruggen, P., Human tumor antigens recognized by T lymphocytes, J. Exp. Med., 183, 725-729, 1996.
46. Uyttenhove, C., Godfraind, C., Lethé, B., Amar-Costesec, A., Renauld, J.-C., Gajewski, T. F., Duffour, M.-T., Warnier, G., Boon, T., and Van den Eynde, B., The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen, Int. J. Cancer, 70, 349-356, 1997.